| Crohn Disease

Stelara vs Hulio

Side-by-side clinical, coverage, and cost comparison for crohn disease.

Deep comparison between: Stelara vs Hulio with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHulio has a higher rate of injection site reactions vs Stelara based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Hulio but not Stelara, including UnitedHealthcare

Category

Stelara

Hulio

At A Glance

RouteSC injection

FrequencyEvery 8-12 weeks

ClassIL-12/23 antagonist

RouteSC injection

FrequencyEvery 1-2 weeks

ClassTNF-alpha inhibitor

Indications

Psoriasis vulgaris
Arthritis, Psoriatic
Crohn Disease
Ulcerative Colitis

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Dosing

Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.

Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.

Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some Rheumatoid Arthritis patients not taking concomitant MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile arthritis Patients 2 years of age and older: 15 kg to <30 kg: 20 mg SC every other week; >=30 kg: 40 mg SC every other week.

Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years weighing 17 kg to <40 kg: 80 mg Day 1, 40 mg Day 15, 20 mg every other week; weighing >=40 kg: 160 mg Day 1, 80 mg Day 15, 40 mg every other week.

Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis 80 mg SC initial dose, followed by 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Contraindications

Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA

—

Drug Interactions

969View drug interactions

1222View drug interactions

Adverse Reactions

Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression

Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia

Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, abdominal pain, flu syndrome, hyperlipidemia, back pain, hypercholesterolemia, hypertension, hematuria, alkaline phosphatase increased.

Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, severe hepatic reactions including acute liver failure.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Pharmacology

Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.

Adalimumab-fkjp is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammatory and immune responses in conditions including RA, JIA, PsA, AS, CD, UC, Ps, HS, and UV.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Stelara